List of Excipients in Branded Drug ZANTAC 360 COOL MINT

Generic Drugs Containing ZANTAC 360 COOL MINT

Company	Ingredient	NDC	Excipient
Chattem Inc	famotidine	41167-0364	CELLULOSE, MICROCRYSTALLINE
Chattem Inc	famotidine	41167-0364	FD&C BLUE NO. 1 ALUMINUM LAKE
Chattem Inc	famotidine	41167-0364	FD&C YELLOW NO. 5 ALUMINUM LAKE
Chattem Inc	famotidine	41167-0364	HYDROXYPROPYL CELLULOSE
Chattem Inc	famotidine	41167-0364	HYPROMELLOSE
Chattem Inc	famotidine	41167-0364	MAGNESIUM STEARATE
Chattem Inc	famotidine	41167-0364	SODIUM STARCH GLYCOLATE TYPE A CORN

What are the Most Frequently-Used Excipients in ZANTAC 360 COOL MINT?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 1 ALUMINUM LAKE
1	FD&C YELLOW NO. 5 ALUMINUM LAKE
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	SODIUM STARCH GLYCOLATE TYPE A CORN

Zantac 360 Cool Mint Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 9, 2026

Zantac 360 Cool Mint is an over-the-counter famotidine chewable tablet positioned for rapid heartburn relief without water. Its commercial differentiation depends more on taste, mouthfeel, dose convenience, brand recognition and retail execution than on a broad patent estate. The core formulation uses conventional pharmaceutical excipients, which limits composition-of-matter protection but creates opportunities in sensory performance, low-sugar formats, manufacturing efficiency and private-label competition.

What is Zantac 360 Cool Mint?

Zantac 360 Cool Mint is a famotidine-based OTC acid reducer sold as a mint-flavored chewable tablet. Famotidine is an H2-receptor antagonist that reduces gastric acid secretion. The product is marketed for relief and prevention of heartburn associated with acid indigestion, subject to the applicable Drug Facts labeling.[1]

Attribute	Publicly reported product characteristic
Brand	Zantac 360
Variant	Cool Mint
Active ingredient	Famotidine
Dosage form	Chewable tablet
Market	U.S. OTC gastrointestinal products
Primary use	Heartburn and acid indigestion
Administration	Chewed before swallowing; no water required
Initial consumer positioning	On-the-go, mint-flavored heartburn relief
Regulatory pathway	OTC labeling and applicable FDA OTC requirements
Primary competitors	Pepcid, generic famotidine, store-brand famotidine

Zantac 360 is distinct from the ranitidine-based Zantac products withdrawn from the U.S. market. The product uses famotidine, not ranitidine. This distinction is central to regulatory positioning because the FDA’s ranitidine actions concerned potential NDMA formation and contamination issues associated with ranitidine products, not famotidine products as a class.[2]

What excipients are used in Zantac 360 Cool Mint?

Public labeling for Zantac 360 chewable tablets identifies a conventional excipient system built around a direct-compression or dry-granulation tablet platform. Exact inactive ingredients can vary by strength, market, packaging configuration and manufacturing revision. The label has identified excipient categories including mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, sweeteners, flavoring agents and tablet-processing aids.[1]

Likely functional roles of the excipients

Excipient category	Commercial and technical function
Mannitol	Bulking agent, cooling mouthfeel, sweetness and chewability
Microcrystalline cellulose	Compression support and tablet structure
Crospovidone	Disintegration and breakup after swallowing
Magnesium stearate	Lubrication during tablet manufacture
Povidone or related binder	Granule or tablet strength where required
Sodium starch glycolate	Disintegration support in some formulations
Sucralose or other high-intensity sweetener	Sweetness without conventional sugar loading
Mint flavor	Primary sensory differentiation
Colorants	Product identification and consumer appeal
Aspartame, where used	Sweetness; requires phenylalanine labeling

The excipient strategy has to solve a difficult formulation problem: the tablet must be mechanically strong enough for commercial handling, yet soft and pleasant enough to chew. Famotidine has an intensely bitter pharmaceutical taste, so flavor masking and aftertaste control are critical. A formulation that provides adequate assay and disintegration but produces bitterness after the mint note fades is commercially weaker than a product with slightly higher excipient cost and better sensory acceptance.

How does the Cool Mint formulation create commercial value?

The primary value of the Cool Mint formulation is convenience. Consumers can use a chewable tablet without water, making the product suitable for travel, workplaces, restaurants and nighttime use. The mint profile also connects the product with oral freshness, although the product is not an oral-care product.

High-value formulation attributes

A competitive formulation should target:

1. A short initial bitterness window.
2. A clean mint release rather than a harsh menthol peak.
3. Low chalkiness and low grittiness.
4. Adequate tablet hardness during shipping.
5. Rapid breakup after chewing.
6. Limited hygroscopicity and acceptable shelf stability.
7. Consistent flavor after exposure to heat and humidity.
8. Low tablet weight consistent with consumer acceptability.

Mannitol is commercially useful because it contributes both bulk and a cooling sensation. That cooling effect can reinforce a mint profile, but excessive mannitol or an overly strong mint flavor can produce a medicinal or “cold” sensory experience. Microcrystalline cellulose improves tablet robustness but can increase chalkiness. Crospovidone can support rapid disintegration but may affect mouthfeel if used at an excessive level.

What formulation patents protect Zantac 360 Cool Mint?

No broad, publicly established patent position comparable to a new chemical entity appears to define Zantac 360 Cool Mint. Famotidine itself is a mature active ingredient, and basic famotidine composition patents have long expired. The defensible IP, if any, is more likely to involve formulation details, manufacturing processes, flavor systems, packaging, trademarks or proprietary know-how.

IP category	Likely position for Zantac 360 Cool Mint
Famotidine composition of matter	Expired or commercially unavailable as a blocking right
Basic famotidine use claims	Mature and unlikely to block OTC generic entry
Chewable-tablet formulation	Potentially narrow and jurisdiction-specific
Mint flavor system	Potentially protectable, but difficult to enforce broadly
Taste-masking technology	Potential source of patent or trade-secret protection
Manufacturing process	Potential process patent or confidential know-how
Product name and logo	Trademark protection, not patent protection
Packaging and retail presentation	Trade dress or trademark issues
Orange Book patent listing	Generally not expected for an OTC monograph-style product

The commercial moat is therefore likely to be weak at the molecule level and moderate at the brand, sensory and distribution levels. A competitor could reproduce the therapeutic concept with generic famotidine and a conventional chewable tablet. It would have greater difficulty duplicating the full consumer experience if the branded product has a materially better flavor profile, tablet texture and packaging system.

What is the Orange Book status of Zantac 360 Cool Mint?

Zantac 360 Cool Mint should not be treated as an ordinary prescription NDA product with a conventional Orange Book patent-and-exclusivity profile. FDA’s Orange Book primarily identifies approved drug products and certain patent and exclusivity information associated with approved applications. OTC products marketed under an applicable monograph or other OTC pathway may not have an Orange Book listing comparable to a prescription drug.[3]

The practical result is important:

• Orange Book-based Paragraph IV litigation is not the normal first-line risk for this product.
• Generic and store-brand competition can arise through the OTC framework.
• Trademark, unfair competition and formulation patent disputes remain possible.
• A patent not listed in the Orange Book may still be asserted outside the formal Paragraph IV mechanism, depending on the product and claim.

When does Zantac 360 Cool Mint lose exclusivity?

Zantac 360 Cool Mint has no obvious single patent expiration date that controls market entry. The active ingredient is generic, and OTC competitors can market famotidine products if they satisfy FDA requirements, labeling conditions and manufacturing obligations.

The relevant commercial exclusivity periods are:

Exclusivity mechanism	Relevance
New chemical entity exclusivity	Not applicable to mature famotidine
Prescription NDA exclusivity	Not the main basis for this branded OTC product
OTC monograph access	Allows compliant competitors to enter without relying on brand ownership
Formulation patent term	Relevant only if a valid, enforceable claim covers the specific product
Trademark term	Renewable and potentially long-lived, but protects branding rather than active ingredient
Trade-secret protection	Potentially indefinite if formulation or process information remains confidential

The brand’s practical exclusivity is therefore based on consumer recognition, retailer placement, product reviews, advertising, manufacturing scale and flavor performance.

Are Paragraph IV challenges relevant to Zantac 360 Cool Mint?

Paragraph IV challenges are generally less relevant than they are for a prescription product with Orange Book-listed patents. A generic applicant typically uses Paragraph IV to challenge an Orange Book patent while seeking ANDA approval. A conventional OTC famotidine chewable product may instead enter through the applicable OTC regulatory route.

A competitor could still challenge or design around any asserted formulation patent. The key questions would be:

• Whether the patent claims a specific excipient ratio or process.
• Whether the claim covers the commercial product as sold.
• Whether the claim is listed in the Orange Book.
• Whether the competitor’s tablet uses a materially different flavor or disintegration system.
• Whether the patent survives written-description, enablement, obviousness and anticipation challenges.

For Zantac 360, the most credible competitive route is likely a non-infringing famotidine chewable with a different flavor system, different sweetener combination or different compression process.

What manufacturing and excipient barriers affect generic entry?

The technical barrier is moderate. Famotidine chewable tablets do not require sterile manufacturing, biologic controls or complex delivery equipment. The main risks are sensory, stability and process-related.

Manufacturing risk areas

Taste masking

Famotidine bitterness can require a combination of sweeteners, flavors, pH control and physical coating or granulation. A competitor that relies only on mint flavor may produce an acceptable first impression but a poor lingering taste.

Tablet robustness

A soft chewable tablet can cap, chip or fracture during packaging and transport. A harder tablet can become difficult to chew. The target compression window must balance friability, chewability and disintegration.

Moisture sensitivity

Flavor oils, sweeteners and porous excipient systems can create moisture-management problems. Blister packaging or high-barrier bottles may be needed, increasing packaging cost.

Content uniformity

Low-dose famotidine products require controlled blending to maintain potency uniformity. Segregation risk rises when the active ingredient and excipients have different particle sizes or densities.

Flavor stability

Mint flavor can migrate, volatilize or change during storage. Packaging selection and flavor incorporation method can materially affect shelf life.

These risks are manageable and do not amount to a strong barrier for established OTC manufacturers. They do create opportunities for excipient suppliers, contract manufacturers and private-label operators with better sensory-development capabilities.

What commercial opportunities exist in the excipient strategy?

Sugar-free and lower-calorie positioning

A sugar-free chewable tablet can expand use among consumers who avoid sucrose. Mannitol, sucralose and other high-intensity sweeteners can support this positioning, but gastrointestinal tolerance and labeling must be monitored. Excess polyol exposure can cause digestive discomfort in sensitive consumers.

Improved taste masking

Excipient suppliers can pursue proprietary taste-masking systems using coated famotidine particles, ion-exchange resins, lipid barriers or polymeric coatings. The strongest opportunity is not a generic “mint tablet,” but a formulation that reduces bitterness while preserving rapid release.

Premium sensory formats

Potential extensions include:

• Peppermint and spearmint variants.
• Cooling-mint tablets with lower flavor intensity.
• Smaller tablets for discreet use.
• Dual-layer chewable tablets.
• Fast-dissolving or orally disintegrating formats.
• Individually wrapped tablets for travel.
• Child-resistant, moisture-resistant packaging.

Each format must remain consistent with OTC labeling and consumer-safety requirements. A new dosage form may require a separate FDA regulatory assessment rather than simple line extension treatment.

Private-label and retailer products

Store-brand famotidine products can compete on price while using familiar excipients. Retailers may seek differentiated formulations that avoid direct replication of the Zantac 360 sensory profile. Contract manufacturers can offer prevalidated chewable platforms with interchangeable flavor systems and brand-specific packaging.

Excipient substitution

There is commercial value in developing substitute systems for:

• Magnesium stearate, where lubricant perception or processing performance is problematic.
• Artificial sweeteners, where consumer demand favors alternative sweeteners.
• Synthetic colors, where clean-label positioning is commercially important.
• Conventional binders, where direct compression improves production economics.

Substitution requires comparative work on hardness, friability, dissolution, flavor release, stability and scale-up performance.

How does Zantac 360 compare with Pepcid and generic famotidine?

Factor	Zantac 360 Cool Mint	Pepcid products	Generic famotidine
Active ingredient	Famotidine	Famotidine	Famotidine
Core differentiation	Brand, chewability and mint sensory profile	Brand and product-format breadth	Price and availability
Patent dependence	Limited apparent dependence	Limited at active-ingredient level	Low
Consumer proposition	No-water mint chewable	Broad acid-reducer portfolio	Value-oriented relief
Retail strength	Strong legacy brand recognition	Strong H2-blocker recognition	Strong price competition
Main vulnerability	Easy therapeutic substitution	Brand saturation	Variable taste and tablet experience
Best defensive lever	Flavor, packaging, marketing and distribution	Brand breadth and channel coverage	Low cost

Zantac 360 competes in a mature category where active-ingredient differentiation is minimal. Its success depends on whether consumers value the product experience enough to pay a premium over generic famotidine.

What is the FDA regulatory status of Zantac 360?

Zantac 360 is an OTC famotidine product marketed under FDA requirements applicable to OTC acid-reducer products and Drug Facts labeling. The product must comply with active-ingredient conditions, dosage limits, warnings, directions, manufacturing controls and labeling requirements.[1][4]

The prior ranitidine withdrawal does not establish a regulatory defect in famotidine. FDA’s 2020 request that ranitidine products be removed from the market addressed ranitidine and NDMA concerns specific to that product class.[2]

A reformulator should treat changes to active-ingredient amount, dosage form, route, labeling claims or consumer population as potential regulatory changes rather than ordinary excipient substitutions.

What licensing deals and litigation affect Zantac 360?

The Zantac brand has changed hands across pharmaceutical and consumer-health businesses. Publicly reported ownership and operating arrangements have included Sanofi’s consumer-health operations and the subsequent Opella structure. Brand ownership, manufacturing rights and regional commercialization rights should be separated from product-specific formulation rights.[5]

The major U.S. Zantac litigation has centered on ranitidine allegations, NDMA exposure and product-liability claims. That litigation is not equivalent to a patent dispute over famotidine chewable tablets. It may still affect brand perception, legal budgets, retailer decisions and marketing strategy.

No major publicly established patent settlement controlling generic entry for Zantac 360 Cool Mint is apparent. The commercial risk is better characterized as competitive substitution than as a scheduled patent cliff.

How strong is the patent estate for Zantac 360 Cool Mint?

The patent estate appears weak to moderate, depending on the existence and scope of formulation-specific rights that are not evident from the brand alone.

Dimension	Assessment
Active ingredient protection	Weak; famotidine is mature
Basic therapeutic use	Weak
Chewable dosage form	Potentially moderate if narrowly claimed
Taste masking	Potentially moderate to strong if supported by valid claims and data
Mint flavor	Weak as a broad patent category
Manufacturing process	Potentially moderate, particularly for confidential know-how
Trademark protection	Stronger than patent protection for brand identity
Generic-entry resistance	Low to moderate
Biosimilar exposure	None

A business acquiring or licensing the product should value brand equity, retail access, formulation know-how and supply reliability more heavily than an assumed patent moat.

What generic launch scenarios exist?

Low-cost direct substitute

A manufacturer launches a standard famotidine chewable or tablet under a store brand. This is the most credible threat and can pressure price without copying the Zantac trade dress.

Sensory-focused challenger

A competitor launches a better-tasting mint product with a lower price. This could erode the premium if consumers perceive no therapeutic difference between products.

Format challenger

A competitor uses orally disintegrating tablets, individually wrapped doses or a smaller chewable tablet. Convenience may shift demand away from the existing product.

Retailer-exclusive product

A major pharmacy or mass retailer introduces private-label famotidine with comparable dosing and a simpler package. Retail placement can offset the absence of brand recognition.

Premium reformulation

The brand owner introduces a sugar-free, cleaner-label or improved taste-masked version. This can defend shelf space but increases development and regulatory costs.

Key Takeaways

• Zantac 360 Cool Mint uses famotidine in a mint-flavored chewable OTC format.
• Its principal commercial protection is brand recognition and consumer experience, not molecule-level exclusivity.
• Mannitol, microcrystalline cellulose, disintegrants, lubricants, sweeteners and mint flavor form the likely excipient platform.
• Taste masking is the most valuable formulation-development opportunity because famotidine is bitter.
• The product is not exposed to biosimilar competition.
• Paragraph IV litigation is unlikely to be the primary generic-entry mechanism unless a relevant Orange Book-listed patent exists.
• Generic and private-label competition can enter through the OTC framework.
• The strongest licensing opportunities involve taste-masking technology, sugar-free formats, premium packaging and regional commercialization.
• Manufacturing barriers are manageable but include flavor stability, moisture control, tablet robustness and content uniformity.
• Any acquisition or licensing valuation should emphasize the Zantac trademark, retail reach and formulation know-how rather than an assumed blocking patent estate.

FAQs About Zantac 360 Cool Mint

Is Zantac 360 Cool Mint the same drug as the old Zantac?

No. Zantac 360 Cool Mint contains famotidine. The former prescription and OTC Zantac products primarily contained ranitidine.

Can a company launch a generic Zantac 360 Cool Mint product?

A company can potentially launch a compliant OTC famotidine chewable product, but it must meet FDA requirements, use permitted labeling and avoid infringing valid formulation, trademark or trade-dress rights.

Which excipient is most important for Zantac 360 taste?

No single excipient controls the entire taste profile. The result depends on the combined use of sweeteners, mannitol, mint flavor, particle engineering, binders and disintegration materials.

Does Zantac 360 Cool Mint have biosimilar risk?

No. Famotidine is a small-molecule drug, so the relevant competitive threats are generic and private-label products rather than biosimilars.

What is the best commercial opportunity for a competing product?

The strongest opportunity is a lower-cost or better-tasting famotidine chewable with improved packaging, a sugar-free profile or a more convenient individually wrapped format.

References

1. DailyMed. (n.d.). Zantac 360 famotidine tablet, chewable: Drug label information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (2020). FDA requests removal of all ranitidine products from the market. https://www.fda.gov/
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (n.d.). Over-the-counter medicines: Drug facts label. https://www.fda.gov/drugs/understanding-over-counter-medicines
5. Opella. (2024). Opella company information and consumer healthcare portfolio. https://www.opella.com/